ArticleGeneral thoracic and cardiovascular surgery2026
Trends in thymectomy for myasthenia gravis in Japan: analysis of a nationwide surgical registry from 1996 to 2023.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThymectomy for generalized myasthenia gravis (MG) without thymoma and with anti-acetylcholine receptor antibody gained evidence-based support following the publication of the MGTX study in 2016, demonstrating its therapeutic efficacy. Consequently, the number of thymectomies increased in the United States. Trends in thymectomy for this condition in Japan is investigated.
methodsThymectomy reported in The Japanese Association for Thoracic Surgery (JATS) Annual Report from 1996 to 2023 was analyzed. Annual numbers of thymectomies were reviewed according to surgical approach, non-thymomatous MG, thymomatous MG, and operative mortality.
resultsA total of 91,087 thymic surgeries were reported from 693 certified institutions. The annual number of thymectomies for MG remained stable. Thymectomy for thymomatous MG increased from 182 cases in 1996 to 380 in 2023, whereas that for non-thymomatous MG declined from its peak of 375 cases in 2001 to 97 in 2023. Overall postoperative hospital mortality of non-thymomatous MG was 0.26%. Thymectomy for thymoma, in contrast, markedly increased from 812 cases in 1996 to 2210 in 2023. The proportion of minimally invasive procedures (VATS/RATS) gradually increased.
conclusionsOpposing trends were observed: a decline in thymectomy for non-thymomatous MG, an increase in thymoma resection, and widespread adoption of minimally invasive procedures with excellent safety. The optional status of thymectomy in Japanese MG guidelines may contribute to this pattern. Considering the long-term symptom relief achieved by surgery and the high ongoing cost of biologic drugs, thymectomy remains a rational therapeutic option. Future treatment strategies should integrate surgical safety with long-term economic perspectives.
Indexed as
Identifiers
41484314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.